The conversation around weight loss has shifted in recent years from diets and surgery to innovative medications. At the centre of this discussion are two drugs, Mounjaro (tirzepatide) and Ozempic (semaglutide). Both belong to the GLP-1 class of medications and were originally designed to manage type 2 diabetes.
Continue Reading on India Today
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.